OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:34 UTC. Every row links to its source record.

GATA3 GATA binding protein 3

ENSG00000107485 · protein coding · Open Targets profile

Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses. Positively regulates ASB2 expression (By similarity). Coordinates macrophage transcriptional activation and UCP2-dependent metabolic reprogramming in response to IL33. Upon tissue injury, acts downstream of IL33 signaling to drive differentiation of inflammation-resolving alternatively activated macrophages. {ECO:0000250|UniProtKB:P23772, ECO:0000269|PubMed:23824597}.

In 9 of 15 cancers, the evidence for GATA3 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemia: somatic 0.30B-cell acute lymphoblastic leukemia: germline 0.91breast adenocarcinomabreast adenocarcinomabreast adenocarcinoma: somatic 0.85Hodgkins lymphomaHodgkins lymphomaHodgkins lymphoma: somatic 0.30Hodgkins lymphoma: germline 0.78nasal cavity polypnasal cavity polypnasal cavity polyp: germline 0.84breast carcinomabreast carcinomabreast carcinoma: somatic 0.61acute lymphoblastic leukemiaacute lymphoblastic leukemiaacute lymphoblastic leukemia: somatic 0.33acute lymphoblastic leukemia: germline 0.58invasive breast carcinomainvasive breast carcinomainvasive breast carcinoma: somatic 0.61adult T-cell leukemia/lymphomaadult T-cell leukemia/lymphomaadult T-cell leukemia/lymphoma: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61female breast carcinomafemale breast carcinomafemale breast carcinoma: somatic 0.61breast carcinoma by gene expression pro…breast carcinoma by gene expression profilebreast carcinoma by gene expression profile: somatic 0.61nodular sclerosis classical Hodgkin lym…nodular sclerosis classical Hodgkin lymphomanodular sclerosis classical Hodgkin lymphoma: germline 0.57colorectal cancercolorectal cancercolorectal cancer: germline 0.55hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.46bladder transitional cell carcinomabladder transitional cell carcinomabladder transitional cell carcinoma: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
Database Ubiquitination

gnomAD loss of function constraint: o/e 0.166470006108284 (upper bound 0.32857000827789307). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of GATA3's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of GATA3's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.